Therapeutic focus
An urgent, unmet need: high-burden CNS diseases
Solvonis is developing breakthrough therapeutic solutions for high-burden CNS (central nervous system) diseases, across three strategic pillars: addiction, psychiatry and neurology.
We’re redefining outcomes for complex conditions with few or no treatment options. Some pose enormous public health concerns. All are characterised by great human suffering.
Through innovative, effective therapies, we aim to provide hope to patients, families and communities – giving millions of people the chance to live healthier, happier lives.
Two strategic pillars:
Addiction
In development:
Alcohol Use Disorder (AUD)
AUD is defined as compulsive, harmful drinking, and is associated with significant health risks, including chronic diseases, mental health conditions and accidents, injuries and violence.
Rates of AUD have risen since Covid, affecting approximately 29 million adults in the US, and a further 11 million in key European markets. Yet just 10% of sufferers seek treatment. Of those, up to 75% relapse within 12 months. This combination of high prevalence and low treatment success rates poses a serious challenge for public health policy.
Cocaine and Methamphetamine Use Disorders
Stimulant use disorder is a significant public health problem and is associated with increased mortality, poor mental health and higher incidence of HIV and hepatitis C. It affects around 2.6 million adults in the US, and up to 600,000 adults in other key markets. There are no approved therapies for Cocaine and Methamphetamine Use Disorders.
Psychiatry
In development:
Post-Traumatic Stress Disorder (PTSD)
PTSD is a complex and debilitating mental health condition that develops in some people who have experienced a traumatic event. Symptoms include intrusive memories, flashbacks, nightmares and avoidant behaviour.
PTSD is estimated to affect 13 million adults in the US, and a further 7 million in key European markets. Many sufferers don’t seek help, and the condition is underdiagnosed and underserved. There are no FDA-approved drug therapies for PTSD.